	US 12,264,131 B2
	Pharmaceutically acceptable salts and compositions thereof
Jason Gray, Oxford (GB); Susana Del Rio Gancedo, Oxford (GB); Dita Davis, Oxford (GB); David James Pearson, Oxford (GB); and Daniel Rixson, Oxford (GB)
Assigned to Beckley Psytech Limited, Oxford (GB)
Filed by BECKLEY PSYTECH LIMITED, Oxford (GB)
Filed on Aug. 4, 2023, as Appl. No. 18/365,699.
Application 18/365,699 is a continuation of application No. 17/941,410, filed on Sep. 9, 2022, granted, now 11,773,063.
Claims priority of application No. 2212116 (GB), filed on Aug. 19, 2022.
Prior Publication US 2024/0101514 A1, Mar. 28, 2024
Int. Cl. C07D 209/16 (2006.01)

CPC C07D 209/16 (2013.01) [C07B 2200/13 (2013.01)]

20 Claims

1. A method of treating a disease or condition in a subject in need thereof, the method comprising administering to a subject a dose of a pharmaceutically acceptable composition formulated for nasal delivery as a dry powder comprising crystalline 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) hydrobromide as characterised by peaks in an x-ray powder diffraction (XRPD) diffractogram at:

a. 2θ values of 14.6°±0.1°, 16.8°±0.1°, 20.8°±0.1°, 24.3°±0.1°, 24.9°±0.1°, and 27.5°±0.1° as measured using an x-ray wavelength of 1.5406 Å;

b. 2θ values of 14.6°±0.1°, 21.6° 0.1°, and 24.3°±0.1° as measured using an x-ray wavelength of 1.5406 Å; or

c. 2θ values of 18.6°±0.1°, 19.7°±0.1°, and 24.8°±0.1° as measured using an x-ray wavelength of 1.5406 Å;

and one or more pharmaceutically acceptable excipients, wherein the dry powder comprises particles having a median diameter of less than 2000 μm, and wherein the disease or condition is depression.